Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes

2014-08-27 03:23:43 | BioPortfolio


ARRY-403 is an investigational new drug being developed by Array BioPharma Inc. for treating Type 2 diabetes. The purpose of this study is to test the safety (potential side effects) and efficacy (potential effects) of the new study drug.

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator)


Type 2 Diabetes


ARRY-403, Placebo


Profil Institute for Clinical Research, Inc.
Chula Vista
United States




Array BioPharma

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:23:43-0400

Clinical Trials [3750 Associated Clinical Trials listed on BioPortfolio]

Analgesic Efficacy Study of ARRY-371797 in Subjects Undergoing Third Molar Extraction

This study will allow us to expand our understanding of ARRY-371797 efficacy in a postoperative pain model by evaluating dose response relationship of ARRY-371797, and by comparing the ons...

Single Day and Multiple Day Ascending Dose Study of ARRY-371797 in Healthy Volunteers

Randomized, double-blind, placebo-controlled study to evaluate safety and pharmacokinetics of ARRY-371797 given to healthy volunteers

Assess Pharmacokinetics of ARRY-371797 in Rheumatoid Arthritis Patients, and the Potential Interactions With Methotrexate and Food

Randomized, double-blind, placebo-controlled study to assess the pharmacokinetics, safety, and efficacy of ARRY-371797 given to patients with Rheumatoid Arthritis who are also on stable do...

The Analgesic Efficacy of Oral ARRY-371797 on Subjects Undergoing Third Molar Extraction

This study is designed to assess the analgesic effect of oral ARRY-371797 doses either perioperatively, or postoperatively following elective surgical removal of impacted third molars.

Phase I/II Study of ARRY-520 in Subjects With Advanced Myeloid Leukemia

ARRY-520 is designed to prevent cancer cells from reproducing. By preventing the tumor cells from reproducing, ARRY-520 may slow the spread of the cancer cells and may cause them to die. A...

PubMed Articles [10288 Associated PubMed Articles listed on BioPortfolio]

Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16 week randomized, double-blind, placebo-controlled multicentre trial.

To assess the effects of 16 weeks of tofogliflozin (sodium/glucose co-transporter 2 (SGLT2) inhibitor) treatment versus placebo on glycosylated haemoglobin (HbA1c) levels in Japanese patients with typ...

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.

This phase 3, randomized, double-blind 24-week study with extension to 1 year assessed efficacy and safety of albiglutide compared with placebo in Japanese patients with type 2 diabetes mellitus (T2DM...

Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.

Glucagon-like peptide-1 (GLP-1) receptor agonists are effective therapies for the treatment of type 2 diabetes and are all currently available as an injection.

Fasiglifam for glycemic control in patients with type 2 diabetes: a phase 3, placebo-controlled study.

To investigate the effect of fasiglifam on glycemic control in patients with type 2 diabetes mellitus (T2DM).

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Background The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown. Methods We randomly assigned patients with type 2 diabe...

Medical and Biotech [MESH] Definitions

The time period before the development of symptomatic diabetes. For example, certain risk factors can be observed in subjects who subsequently develop INSULIN RESISTANCE as in type 2 diabetes (DIABETES MELLITUS, TYPE 2).

A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.

A severe type of hyperlipidemia, sometimes familial, that it is characterized by the elevation of both plasma CHYLOMICRONS and TRIGLYCERIDES contained in VERY-LOW-DENSITY LIPOPROTEINS. Type V hyperlipoproteinemia is often associated with DIABETES MELLITUS and is not caused by reduced LIPOPROTEIN LIPASE activity as in HYPERLIPOPROTEINEMIA TYPE I .

Urination of a large volume of urine with an increase in urinary frequency, commonly seen in diabetes (DIABETES MELLITUS; DIABETES INSIPIDUS).

A subtype of DIABETES MELLITUS that is characterized by INSULIN deficiency. It is manifested by the sudden onset of severe HYPERGLYCEMIA, rapid progression to DIABETIC KETOACIDOSIS, and DEATH unless treated with insulin. The disease may occur at any age, but is most common in childhood or adolescence.

More From BioPortfolio on "Single Ascending Dose Phase 1 Trial in Patients With Type 2 Diabetes"

Quick Search

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

A diagnostic test is any kind of medical test performed to aid in the diagnosis or detection of disease. For example: to diagnose diseases to measure the progress or recovery from disease to confirm that a person is free from disease Clin...

Searches Linking to this Trial